text_1: HRD 肿瘤 患者 队列 包括 根据 my - Choice 检测 , 有 BRCA 突变 肿瘤 或 有 HRD 的 患者 ( 之前 认为 评分 ≥ 33 分 表示 HRD 状态 , 评分 < 33 分 表示 非 HRD 状态 ; 对 既往 临床试验 进行 几项 回顾性 分析 后 , 阈值 评分 被 修订 为 42 分 , 目的 是 以 更 高 的 灵敏度 检测 对 PARP 抑制剂 的 应答 ) 31 - 33 .
  
text_2: the cohort of patients with tumors that had HRD consisted of patients who had tumors that were BRCA @-@ mutated or had HRD according to the myChoice assay ( on which a score of ≥ 33 was considered to indicate HRD status , and a score of < 33 was considered to indicate non @-@ HRD status ; the threshold score was revised from 42 , after several retrospective analyses of previous clinical trials , to increase the sensitivity of detecting a response to PARP inhibitors ) .31 @-@ 33
  